Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate...

Area of Science:

• Oncology
• Immunology
• Clinical Trials

Background:

• Castration-resistant prostate cancer (CRPC) remains a significant clinical challenge, necessitating novel therapeutic strategies.
• Current treatments often involve chemotherapy, but resistance develops, highlighting the need for combination therapies.
• Cancer vaccines aim to harness the immune system to target tumor cells, potentially enhancing existing treatment modalities.

Purpose of the Study:

• To evaluate the efficacy and safety of a novel peptide-based cancer vaccine (KRM-20) in combination with docetaxel and dexamethasone for chemotherapy-naïve CRPC patients.
• To assess the impact of KRM-20 on prostate-specific antigen (PSA) decline, a key marker of treatment response in prostate cancer.
• To investigate the immunogenicity of KRM-20 by measuring human leukocyte antigen (HLA)-matched peptide-specific antibody and cytotoxic T lymphocyte (CTL) responses.

Main Methods:

• A double-blind, placebo-controlled, randomized phase II clinical trial involving chemotherapy-naïve CRPC patients.
• Patients were randomized to receive either KRM-20 plus docetaxel and dexamethasone or placebo plus docetaxel and dexamethasone.
• The primary endpoint was the difference in PSA decline between the two treatment arms. Secondary endpoints included immune responses and survival outcomes.

Main Results:

• The rates of >50% PSA decline were similar between the KRM-20 arm (56.5%) and the placebo arm (53.8%) (P=0.851).
• Significant increases in HLA-matched peptide-specific IgG (P=0.018) and CTL (P=0.007) responses were observed in the KRM-20 arm post-treatment.
• The addition of KRM-20 did not increase toxicity, and there were no significant differences in progression-free or overall survival between the groups.

Conclusions:

• The combination of KRM-20 with docetaxel and dexamethasone was safe and well-tolerated in CRPC patients.
• While KRM-20 demonstrated immunogenicity, it did not significantly enhance PSA decline or survival in this phase II trial.
• Subgroup analyses suggest potential benefit in patients with higher lymphocyte counts or lower PSA levels, warranting further investigation in larger trials.